A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)(+)/CD141 (BDCA-3)(+) myeloid dendritic cells in solid tumors
一项随机 II 期临床试验，研究立体定向放射治疗 (SBRT) 联合全身性帕博利珠单抗，或不联合瘤内注射阿维鲁单抗/伊匹木单抗，以及 CD1c (BDCA-1)(+)/CD141 (BDCA-3)(+) 髓系树突状细胞治疗实体瘤的疗效。
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-024-03751-0
Vounckx, Manon; Tijtgat, Jens; Stevens, Latoya; Dirven, Iris; Ilsen, Bart; Vandenbroucke, Frederik; Raeymaeckers, Steven; Vekens, Karolien; Forsyth, Ramses; Geeraerts, Xenia; Van Riet, Ivan; Schwarze, Julia Katharina; Tuyaerts, Sandra; Decoster, Lore; De Ridder, Mark; Dufait, Ines; Neyns, Bart
CD14
树突状细胞
细胞生物学
树突状细胞
免疫/内分泌
